Editorial Review: The mouth: A gateway or a trap for HIV?

AIDS

Volumn 24, Issue 1, 2010, Pages 5-16

  Malamud, Daniel ^a,b   Wahl, Sharon M ^c  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; ALPHA DEFENSIN; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; BETA DEFENSIN; CELL SURFACE IMMUNOGLOBULIN; FC RECEPTOR; GLYCOPROTEIN; GLYCOPROTEIN 340; GLYCOPROTEIN GP 120; HLA ANTIGEN CLASS 2; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 3; INTERFERON; LACTOFERRIN; LACTOPEROXIDASE; LIPOCORTIN 2; LYSOZYME; MUCIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROLINE; RETINOIC ACID INDUCIBLE PROTEIN I; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; THROMBOSPONDIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; BREAST FEEDING; BREAST MILK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; DENDRITIC CELL; EDITORIAL; EPITHELIUM; GASTROINTESTINAL MUCOSA; HELPER CELL; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFECTION RATE; INFECTION SENSITIVITY; LANGERHANS CELL; MOUTH CAVITY; MOUTH MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; RISK FACTOR; SALIVARY GLAND; TARGET CELL; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; DISEASE TRANSMISSION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PREGNANCY; SALIVA; VIROLOGY;

FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MILK, HUMAN; MOUTH MUCOSA; PREGNANCY; SALIVA;

EID: 73649136118     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328333525f     Document Type: Editorial

References (123)

1. Groopman JE, Salahuddin SZ, Sarngadharan MG, Markham PD, Gonda M, Sliski A, Gallo RC. HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. Science 1984; 226:447-449.
2. Goto Y, Yeh CK, Notkins AL, Prabhakar BS. Detection of proviral sequences in saliva of patients infected with human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1991; 7:343-347.
3. Page-Shafer K, Sweet S, Kassaye S, Ssali C. (C2) Saliva, breast milk, and mucosal fluids in HIV transmission. Adv Dent Res 2006; 19:152-157.
4. Dassey D, Detels R, Visscher B, Rozenbaum W, Gharakhanian S, Gardon B, et al. HIV and orogenital transmission. Lancet 1988; 332:1023-1024.
5. Winkelstein W Jr, Lyman DM, Padian N, Grant R, Samuel M, Wiley JA, et al. Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA 1987; 257:321-325. (Pubitemid 17048862)
6. Shugars DC, Wahl SM. The role of the oral environment in HIV-1 transmission. J Am Dent Assoc 1998; 129:851-858.
7. DeGruttola V, Mayer KH. Human immunodeficiency virus and oral intercourse. Ann Intern Med 1987; 107:428-429.
8. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-264.
9. Page-Shafer K, Shiboski CH, Osmond DH, Dilley J, McFarland W, Shiboski SC, et al. Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men. AIDS 2002; 16:2350-2352. (Pubitemid 35449028)
10. Scully C, Porter S. HIV topic update: oro-genital transmission of HIV. Oral Dis 2000; 6:92-98.
11. Campo J, Perea MA, del Romero J, Cano J, Hernando V, Bascones A. Oral transmission of HIV, reality or fiction? An update. Oral Dis 2006; 12:219-228.
12. Levy JA, Greenspan D. HIV in saliva. Lancet 1988; 2:1248.
13. Ho DD, Byington RE, Schooley RT, Flynn T, Rota TR, Hirsch MS. Infrequency of isolation of HTLV-III virus from saliva in AIDS. N Engl J Med 1985; 313:1606.
14. Barr CE, Miller LK, Lopez MR, Croxson TS, Schwartz SA, Denman H, Jandorek R. Recovery of infectious HIV-1 from whole saliva. J Am Dent Assoc 1992; 123:36-37; 39-48; discussion 38.
15. John-Stewart GC. Infant feeding and prevention of mother-to-child transmission of HIV-1. Curr Opin HIV AIDS 2008; 3:173-179.
16. Richardson BA, John-Stewart GC, Hughes JP, Nduati R, Mbori-Ngacha D, Overbaugh J, Kreiss JK. Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis 2003; 187:736-740.
17. Farquhar C, VanCott TC, Mbori-Ngacha DA, Horani L, Bosire RK, Kreiss JK, et al. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis 2002; 186:1173-1176.
18. Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, Orenstein JM. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. Oral Dis 1997; 3 (Suppl 1):S64-S69.
19. R memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection. J Virol 2008; 82:471-486.
20. Walter J, Kuhn L, Aldrovandi GM. Advances in basic science understanding of mother-to-child HIV-1 transmission. Curr Opin HIV AIDS 2008; 3:146-150.
21. Hussain LA, Lehner T. Comparative investigation of Langer-hans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology 1995; 85:475-484.
22. Stoddard E, Ni H, Cannon G, Zhou C, Kallenbach N, Malamud D, Weissman D. gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue. J Virol 2009; 83:8596-8603.
23. Smith PD, Roberts CM. American College Health Association annual Pap test and sexually transmitted infection survey: 2006. J Am Coll Health 2009; 57:389-394.
24. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(R) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009; 2:412-426.
25. Moutsopoulos NM, Nares S, Nikitakis N, Rangel Z, Wen J, Munson P, et al. Tonsil epithelial factors may influence oropharyngeal human immunodeficiency virus transmission. Am J Pathol 2007; 171:571-579.
26. Liu X, Zha J, Chen H, Nishitani J, Camargo P, Cole SW, Zack JA. Human immunodeficiency virus type 1 infection and replication in normal human oral keratinocytes. J Virol 2003; 77:3470-3476.
27. Kumar RB, Maher DM, Herzberg MC, Southern PJ. Expression of HIV receptors, alternate receptors and co-receptors on tonsillar epithelium: implications for HIV binding and primary oral infection. Virol J 2006; 3:25.
28. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, Von Andrian UH. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003; 424:88-93.
29. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008; 9:301-309.
30. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005; 5:783-792.
31. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hira-sawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992; 10:75-88.
32. Lehner T, Wang Y, Pido-Lopez J, Whittall T, Bergmeier LA, Babaahmady K. The emerging role of innate immunity in protection against HIV-1 infection. Vaccine 2008; 26:2997-3001.
33. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 2006; 203:41-46.
34. Peng G, Greenwell-Wild T, Nares S, Jin W, Lei KJ, Rangel ZG, et al. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 2007; 110:393-400.
35. Greenwell-Wild T, Vazquez N, Jin W, Rangel Z, Munson P, Wahl SM. IL-27 inhibition of HIV-1 involves an intermediate induction of type I IFN. Blood 2009; 114:1864-1874.
36. Devine DA. Antimicrobial peptides in defence of the oral and respiratory tracts. Mol Immunol 2003; 40:431-443.
37. R T cells. Retrovirology 2009; 6:42.
38. Yurochko AD, Huong SM, Huang ES. Identification of human cytomegalovirus target sequences in the human immunodeficiency virus long terminal repeat. Potential role of IE2-86 binding to sequences between-120 and-20 in promoter transactivation. J Hum Virol 1999; 2:81-90.
39. Mercader M, Nickoloff BJ, Foreman KE. Induction of human immunodeficiency virus 1 replication by human herpesvirus 8. Arch Pathol Lab Med 2001; 125:785-789.
40. Tomas MS, Claudia Otero M, Ocana V, Elena Nader-Macias M. Production of antimicrobial substances by lactic acid bacteria I: determination of hydrogen peroxide. Methods Mol Biol 2004; 268:337-346.
41. Fultz PN. Components of saliva inactivate human immunodeficiency virus. Lancet 1986; 2:1215.
42. Fox PC, Wolff A, Yeh CK, Atkinson JC, Baum BJ. Salivary inhibition of HIV-1 infectivity: functional properties and distribution in men, women, and children. J Am Dent Assoc 1989; 118:709-711.
43. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90:1141-1149.
44. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting antihuman immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96:456-464.
45. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004; 200:1337-1346.
46. Nagashunmugam T, Malamud D, Davis C, Abrams WR, Friedman HM. Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. J Infect Dis 1998; 178:1635-1641.
47. Wu Z, Golub E, Abrams WR, Malamud D. gp340 (SAG) bindsto the V3 sequence of gp120 important for chemokine receptor interaction. AIDS Res Hum Retroviruses 2004; 20:600-607.
48. Wu Z, Lee S, Abrams W, Weissman D, Malamud D. The N-terminal SRCR-SID domain of gp-340 interacts with HIV type 1 gp120 sequences and inhibits viral infection. AIDS Res Hum Retroviruses 2006; 22:508-515.
49. Swart PJ, Kuipers ME, Smit C, Pauwels R, deBethune MP, de Clercq E, et al. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res Hum Retroviruses 1996; 12:769-775.
50. Groot F, Geijtenbeek TB, Sanders RW, Baldwin CE, Sanchez-Hernandez M, Floris R, et al. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN-gp120 interaction. J Virol 2005; 79:3009-3015.
51. Cummins JE Jr, Denniston M, Mayer KH, PickardR, Novak RM, Graham P, et al. Mucosal innate immune factors in secretions from high-risk individuals immunized with a bivalent gp120 vaccine. AIDS Res Hum Retroviruses 2007; 23:748-754.
52. Berkhout B, van Wamel JL, Beljaars L, Meijer DK, Visser S, Floris R. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived pep-tides. Antiviral Res 2002; 55:341-355.
53. Lee-Huang S, Maiorov V, Huang PL, Ng A, Lee HC, Chang YT, et al. Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity. Biochemistry 2005; 44:4648-4655.
54. Crombie R, Silverstein RL, MacLow C, Pearce SF, Nachman RL, Laurence J. Identification of a CD36-related thrombos-pondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva. J Exp Med 1998; 187:25-35.
55. Saeland E, de Jong MA, Nabatov AA, Kalay H, Geijtenbeek TB, van Kooyk Y. MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells. Mol Immunol 2009; 46:2309-2316.
56. Bergey EJ, Cho MI, Blumberg BM, Hammarskjold ML, Rekosh D, Epstein LG, Levine MJ. Interaction of HIV-1 and human salivary mucins. J Acquir Immune Defic Syndr 1994; 7:995-1002.
57. Robinovitch MR, Ashley RL, Iversen JM, Vigoren EM, Oppen-heim FG, Lamkin M. Parotid salivary basic proline-rich proteins inhibit HIV-I infectivity. Oral Dis 2001; 7:86-93.
58. Venkataraman N, Cole AL, Ruchala P, Waring AJ, Lehrer RI, Stuchlik O, et al. Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol 2009; 7:e95.
59. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17:F39-F48.
60. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P. Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 2007; 109:2928-2935.
61. Yamaguchi Y, Semmel M, Stanislawski L, Strosberg AD, Stani-slawski M. Virucidal effects of glucose oxidase and peroxidase or their protein conjugates on human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993; 37:26-31.
62. Xie H, Belogortseva NI, Wu J, Lai WH, Chen CH. Inhibition of human immunodeficiency virus type 1 entry by a binding domain of Porphyromonas gingivalis gingipain. Antimicrob Agents Chemother 2006; 50:3070-3074.
63. Baron S. Oral transmission of HIV, a rarity: emerging hypotheses. J Dent Res 2001; 80:1602-1604.
64. Cole AM, Cole AL. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008; 59:27-34.
65. Chang TL, Klotman ME. Defensins: natural anti-HIV peptides. AIDS Rev 2004; 6:161-168.
66. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7:167-174.
67. Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel antiin-fective and immune therapeutics. Curr Pharm Des 2004; 10:2891-2905.
68. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002; 111:867-878.
69. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997; 99:894-900.
70. Song X, Zeng L, Jin W, Thompson J, Mizel DE, Lei K, et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 1999; 190:535-542.
71. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-Wild T, et al. Secretory leukocyte protease inhibitor mediates nonredundant functions necessary for normal wound healing. Nat Med 2000; 6:1147-1153.
72. Angelov N, Moutsopoulos N, Jeong MJ, Nares S, Ashcroft G, Wahl SM. Aberrant mucosal wound repair in the absence of secretory leukocyte protease inhibitor. Thromb Haemost 2004; 92:288-297.
73. Wahl SM, Worley P, Jin W, McNeely TB, Eisenberg S, Fasching C, et al. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues. Am J Pathol 1997; 150:1275-1284.
74. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A 1986; 83:6692-6696.
75. Jacobsen LC, Sorensen OE, Cowland JB, Borregaard N, Theil-gaard-Monch K. The secretory leukocyte protease inhibitor (SLPI) and the secondary granule protein lactoferrin are synthesized in myelocytes, colocalize in subcellular fractions of neutrophils, and are coreleased by activated neutrophils. J Leukoc Biol 2008; 83:1155-1164.
76. Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, Blaho JA, Herold BC. Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 2008; 82:9337-9344.
77. Rocha LA, Vargas PA, Silva LF, Leon JE, Santos AB, Hiemstra PS, Mauad T. Expression of secretory leukocyte proteinase inhibitor in the submandibular glands of AIDS patients. Oral Dis 2008; 14:82-88.
78. Mitchell CM, Balkus J, Agnew KJ, Cohn S, Luque A, Lawler R, et al. Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. AIDS Res Hum Retroviruses 2008; 24:667-671.
79. Chattopadhyay A, Gray LR, Patton LL, Caplan DJ, Slade GD, Tien HC, Shugars DC. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun 2004; 72:1956-1963.
80. Jana NK, Gray LR, Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J Virol 2005; 79:6432-6440.
81. King AE, Morgan K, Sallenave JM, Kelly RW. Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone. Biochem Biophys Res Commun 2003; 310:594-599.
82. Sallenave JM, Si Tahar M, Cox G, Chignard M, Gauldie J. Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leukoc Biol 1997; 61:695-702.
83. Pillay K, Coutsoudis A, Agadzi-Naqvi AK, Kuhn L, Coovadia HM, Janoff EN. Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183:653-656.
84. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banat-vala JE, Challacombe SJ. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 2006; 13:1111-1118.
85. Morel E, Gruenberg J. Annexin A2 binding to endosomes and functions in endosomal transport are regulated by tyrosine 23 phosphorylation. J Biol Chem 2009; 284:1604-1611.
86. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009; 137:433-444.
87. Callahan MK, Popernack PM, Tsutsui S, Truong L, Schlegel RA, Henderson AJ. Phosphatidylserine on HIV envelope is a co-factor for infection of monocytic cells. J Immunol 2003; 170:4840-4845.
88. Orenstein JM, Meltzer MS, Phipps T, Gendelman HE. Cyto-plasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastruc-tural study. J Virol 1988; 62:2578-2586.
89. Ryzhova EV, Vos RM, Albright AV, Harrist AV, Harvey T, Gonzalez-Scarano F. Annexin 2: a novel human immunodeficiency virus type 1 Gag binding protein involved in replication in monocyte-derived macrophages. J Virol 2006; 80:2694-2704.
90. Verani A, Gras G, Pancino G. Macrophages and HIV-1: dangerous liaisons. Mol Immunol 2005; 42:195-212.
91. Shugars DC, Sauls DL, Weinberg JB. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lym-phocytotropic strains of human immunodeficiency virus type I. Oral Dis 1997; 3 (Suppl 1):S70-S72.
92. Hocini H, Becquart P, Bouhlal H, Adle-Biassette H, Kazatchkine MD, Belec L. Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin Diagn Lab Immunol 2000; 7:515-518.
93. Py B, Basmaciogullari S, Bouchet J, Zarka M, Moura IC, Benhamou M, et al. The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS One 2009; 4:e5006.
94. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326:711-713.
95. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202:1659-1668.
96. Zhu J, Nathan C, Ding A. Suppression of macrophage responses to bacterial lipopolysaccharide by a nonsecretory form of secretory leukocyte protease inhibitor. Biochim Bio-phys Acta 1999; 1451:219-223.
97. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leu-koprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993; 148:1056-1060.
98. Rundegren J. Calcium-dependent salivary agglutinin with reactivity to various oral bacterial species. Infect Immun 1986; 53:173-178.
99. Demuth DR, Lammey MS, Huck M, Lally ET, Malamud D. Comparison of Streptococcus mutans and Streptococcus san-guis receptors for human salivary agglutinin. Microb Pathog 1990; 9:199-211.
100. Demuth DR, Golub EE, Malamud D. Streptococcal-host interactions. Structural and functional analysis of a Streptococcus sanguis receptor for a human salivary glycoprotein. J Biol Chem 1990; 265:7120-7126.
101. Bikker FJ, Ligtenberg AJ, End C, Renner M, Blaich S, Lyer S, et al. Bacteria binding by DMBT1/SAG/gp-340 is confined to the VEVLXXXXW motif in its scavenger receptor cysteine-rich domains. J Biol Chem 2004; 279:47699-47703.
102. Loimaranta V, Jakubovics NS, Hytonen J, Finne J, Jenkinson HF, Stromberg N. Fluid-or surface-phase human salivary scavenger protein gp340 exposes different bacterial recognition properties. Infect Immun 2005; 73:2245-2252.
103. Prakobphol A, Xu F, Hoang VM, Larsson T, Bergstrom J, Johansson I, et al. Salivary agglutinin, which binds Streptococcus mutans and Helicobacter pylori, is the lung scavenger receptor cysteine-rich protein gp-340. J Biol Chem 2000; 275:39860-39866.
104. Vijayakumar S, Takito J, Gao X, Schwartz GJ, Al-Awqati Q. Differentiation of columnar epithelia: the hensin pathway. J Cell Sci 2006; 119:4797-4801.
105. Kang W, Reid KB. DMBT1, a regulator of mucosal home-ostasis through the linking of mucosal defense and regeneration? FEBS Lett 2003; 540:21-25.
106. Conde AR, Martins AP, Brito M, Manuel A, Ramos S, Malta-Vacas J, et al. DMBT1 is frequently downregulated in well differentiated gastric carcinoma but more frequently upre-gulated across various gastric cancer types. Int J Oncol 2007; 30:1441-1446.
107. Sarrias MR, Gronlund J, Padilla O, Madsen J, Holmskov U, Lozano F. The scavenger receptor cysteine-rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit Rev Immunol 2004; 24:1-37.
108. Holmskov U, Mollenhauer J, Madsen J, Vitved L, Gronlund J, Tornoe I, et al. Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D. Proc Natl Acad Sci U S A 1999; 96:10794-10799.
109. Hohenester E, Sasaki T, Timpl R. Crystal structure of a scavenger receptor cysteine-rich domain sheds light on an ancient superfamily. Nat Struct Biol 1999; 6:228-232.
110. Ligtenberg AJ, Veerman EC, Nieuw Amerongen AV, Mollen-hauer J. Salivary agglutinin/glycoprotein-340/DMBT1: a single molecule with variable composition and with different functions in infection, inflammation and cancer. Biol Chem 2007; 388:1275-1289.
111. Cannon G, Yi Y, Ni H, Stoddard E, Scales DA, Van Ryk DI, et al. HIV envelope binding by macrophage-expressed gp340 promotes HIV-1 infection. J Immunol 2008; 181:2065-2070.
112. Malamud D, Nagashunmugam T, Davis C, Kennedy S, Abrams WR, Kream R, Friedman HM. Inhibition of HIV infectivity by human saliva. Oral Dis 1997; 3 (Suppl 1):S58-S63.
113. White MR, Crouch E, van Eijk M, Hartshorn M, Pemberton L, Tornoe I, et al. Cooperative anti-influenza activities of respiratory innate immune proteins and neuraminidase inhibitor. Am J Physiol Lung Cell Mol Physiol 2005; 288:L831-L840.
114. Wu Z, Van Ryk D, Davis C, Abrams WR, ChaikenI, Magnani J, Malamud D. Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. AIDS Res Hum Retroviruses 2003; 19:201-209.
115. Nagashunmugam T, Friedman HM, Davis C, Kennedy S, Goldstein LT, Malamud D. Human submandibular saliva specifically inhibits HIV type 1. AIDS Res Hum Retroviruses 1997; 13:371-376.
116. Malamud D, Christensen CM, Navazesh M, Davis C. Bacterial agglutinin activity in the saliva of human identical and fraternal twins. Arch Oral Biol 1988; 33:801-805.
117. Takano K, Malamud D, Bennick A, Oppenheim F, Hand AR. Localization of salivary proteins in granules of human parotid and submandibular acinar cells. Crit Rev Oral Biol Med 1993; 4:399-405.
118. Takano K, Bogert M, Malamud D, Lally E, Hand AR. Differential distribution of salivary agglutinin and amylase in the Golgi apparatus and secretory granules of human salivary gland acinar cells. Anat Rec 1991; 230:307-318.
119. Bikker FJ, Ligtenberg AJ, van der Wal JE, van den Keijbus PA, Holmskov U, Veerman EC, Nieuw Amerongen AV. Immuno-histochemical detection of salivary agglutinin/gp-340 in human parotid, submandibular, and labial salivary glands. J Dent Res 2002; 81:134-139.
120. Cummins JE, Christensen L, Lennox JL, Bush TJ, Wu Z, Malamud D, et al. Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retro-viruses 2006; 22:788-795.
121. Stoddard E, Cannon G, Ni H, Kariko K, Capodici J, Malamud D, Weissman D. gp340 expressed on human genital epithelia binds HIV-1 envelope protein and facilitates viral transmission. J Immunol 2007; 179:3126-3132.
122. Fichorova RN, Rheinwald JG, Anderson DJ. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol Reprod 1997; 57:847-855.
123. Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, Kahn B, Gallay PA. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol 2007; 81:395-405.